Home › Bronchial Cancer › California › Los Angeles
Bronchial Cancer clinical trials in Los Angeles, CA
3 studies for Bronchial Cancer are looking for participants at sites in and around Los Angeles (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- Cedars-Sinai Medical Center, Los Angeles
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RecruitingPhase 3
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RecruitingPhase 1/2
- The Angeles Clinic and Research Institute, Los Angeles
Bronchial Cancer trials in other cities
- New York City, NY6 studies
- Houston, TX5 studies
- Columbus, OH4 studies
- Boston, MA4 studies
- Pittsburgh, PA4 studies
- Memphis, TN3 studies
- Chicago, IL3 studies
- Minneapolis, MN3 studies
- Cincinnati, OH3 studies
- Durham, NC3 studies
- Tampa, FL3 studies
- Arlington, VA3 studies
Other studies in Los Angeles
- Non-Small Cell Lung Cancer87 studies
- Cancer (all types)74 studies
- Breast Cancer73 studies
- Prostate Cancer61 studies
- Colorectal Cancer59 studies
- Metastatic Cancer57 studies
- Ovarian Cancer50 studies
- Lung Cancer45 studies
- Head and Neck Squamous Cell Carcinoma42 studies
- Pancreatic Cancer35 studies
- Endometrial Cancer34 studies
- Melanoma34 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.